Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma in Situ: early-phase trial registry
3 of 5 indexed Carcinoma in Situ trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Carcinoma in Situ: 5 US clinical trials tracked, 3 recruiting.
Carcinoma in Situ is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 2 of these trials.
Enrollment posture brief
Registry condition carcinoma-in-situ
OPEN 3 | RECR 60% | LATE 1 | EARLY 3 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Carcinoma in Situ lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma in Situ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma in Situ is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Carcinoma in Situ research.
Children's Oncology Group accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma in Situ enrolment sits around 300 participants.
Median target enrolment is 300 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Carcinoma in Situ research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
NCT02402244
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Merck Sharp & Dohme
NCT06833073
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine
NCT06022029
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
Children's Oncology Group
NCT03223753
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
Endo Pharmaceuticals
NCT01316874
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma in Situ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma in Situ trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma in Situ page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Carcinoma in Situ trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Children's Oncology Group sponsors the most Carcinoma in Situ trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma in Situ condition card totals 5 registered trials; most-linked intervention Valrubicin, 800 mg; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.